article thumbnail

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Imaging Technology

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1, and an MEK inhibitor.

article thumbnail

TeleDaaS Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations

Imaging Technology

Radiopharmaceuticals are revolutionizing modern cancer treatment and precision dosimetry is a crucial component of this advanced therapy. This is already showing promise with several ongoing trials of approved and developmental radiopharmaceuticals.

Clinic 54